Investigating prospective longitudinal chemotherapy effects on TCR/BCR-repertoire, assessing the functionality of other immune cell types besides neutrophils, and exploring potential epigenetic rewiring are important to fully understand the impact of standard-of-care chemotherapy in breast cancer patients. The gene discussed is BCR; the disease is breast cancer.